Patients undergo first doses of GE HealthCare's PET radiotracer Flyrcado (flurpiridaz F 18) injection at early adopter sites ...

GE HealthCare (GEHC) has delivered the first patient doses of Flyrcado or flurpiridaz F 18 njection, a first-of-its-kind unit dose positron ...

The first patient doses of GE HealthCare’s new FDA-approved PET radiotracer, Flyrcado ™ (flurpiridaz F 18) injection, are being administered at early adopter sites around the United States.

GE HealthCare (Nasdaq: GEHC) has delivered the first patient doses of Flyrcado™ (flurpiridaz F 18) injection, a first-of-its-kind unit dose positron emission tomography myocardial perfusion ...

GE HealthCare has delivered the initial subject doses of Flyrcado (flurpiridaz F 18) injection, for coronary artery disease ...

Discover GE HealthCare's Q4 2024 insights: record $19.8B backlog, 18.7% margin growth, and Flyrcado's 2025 launch.

The company announced the planned launch of Flyrcado, a radiopharmaceutical product for myocardial perfusion imaging, in April 2025. It is expected to generate $30 million in revenue for 2025 and ...

February 13, 2025GE HealthCare Technologies Inc. beats earnings expectations. Reported EPS is $1.45, expectations were $1.26.

For example, our cath lab, Allia IGS Pulse is outperforming our expectations and we're on track to launch Flyrcado in the near term. We continued to advance our leadership position in AI. In one year, ...

The largest life sciences association in the state recognized those driving discovery during its 32nd annual dinner meeting ...